Etidronate Does Not Suppress Periprosthetic Bone Loss Following Cemented Hip Arthroplasty

Overview

Journal Int Orthop

Specialty Orthopedics

Date 2005 Sep 30

PMID 16193347

Citations 7

Authors

S K Fokter

R Komadina

A Repse-Fokter

S A Yerby

A Kocijancic

J Marc

Affiliations

Soon will be listed here.

Abstract

Periprosthetic bone loss after arthroplasty may threaten prosthesis survival. The current study investigated the effect of etidronate therapy on periprosthetic, contralateral hip, and spine bone mineral density (BMD) in a one-year, prospective, randomized, double-blind study on 46 patients after cemented hip arthroplasty. BMD was measured with dual-energy X-ray absorptiometry (DXA). There were no significant differences between mean BMD measurements of the etidronate and placebo groups, with the exception of the mean percent change in the spine at six months and 12 months and in Gruen zone 3 at six months; in all three cases, the etidronate group had significantly greater mean values. These findings suggest that cyclic etidronate therapy has no significant effect in suppressing periprosthetic bone loss following cemented hip arthroplasty.

Citing Articles

Comparing the Efficacy of Antiosteoporotic Drugs in Preventing Periprosthetic Bone Loss Following Total Hip Arthroplasty: A Systematic Review and Bayesian Network Meta-Analysis.

Tang Y, Jin Z, Lu Y, Chen L, Lv S, Xu T Orthop Surg. 2024; 16(10):2344-2354.

PMID: 39056482 PMC: 11456730. DOI: 10.1111/os.14165.

Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.

Sheth N, Smith J, Winzenrieth R, Humbert L, Wang Y, Boxberger J J Bone Joint Surg Am. 2024; 106(13):1162-1170.

PMID: 38691582 PMC: 11594069. DOI: 10.2106/JBJS.23.01334.

Peri-prosthetic bone remodeling and change in bone mineral density in the femur after cemented polished tapered stem implantation.

Iwase T, Morita D, Takemoto G, Fujita H, Katayama N, Otsuka H Eur J Orthop Surg Traumatol. 2019; 29(5):1061-1067.

PMID: 30848380 DOI: 10.1007/s00590-019-02414-6.

Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty.

Nagoya S, Tateda K, Okazaki S, Kosukegawa I, Shimizu J, Yamashita T Eur J Orthop Surg Traumatol. 2018; 28(8):1601-1607.

PMID: 29774416 DOI: 10.1007/s00590-018-2223-x.

Pharmacologic augmentation of implant fixation in osteopenic bone.

Ross R, Hamilton J, Wilson B, Sumner D, Virdi A Curr Osteoporos Rep. 2013; 12(1):55-64.

PMID: 24293098 DOI: 10.1007/s11914-013-0182-z.

References

Duncan C, Masterson E, Masri B . Impaction allografting with cement for the management of femoral bone loss. Orthop Clin North Am. 1998; 29(2):297-305. DOI: 10.1016/s0030-5898(05)70327-8. View

Reiter A, Sabo D, Simank H, Buchner T, Seidel M, Lukoschek M . [Periprosthetic mineral density in cement-free hip replacement arthroplasty]. Z Orthop Ihre Grenzgeb. 1998; 135(6):499-504. DOI: 10.1055/s-2008-1039735. View

Kroger H, Venesmaa P, Jurvelin J, Miettinen H, Suomalainen O, Alhava E . Bone density at the proximal femur after total hip arthroplasty. Clin Orthop Relat Res. 1998; (352):66-74. View

Russell R, Rogers M . Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999; 25(1):97-106. DOI: 10.1016/s8756-3282(99)00116-7. View

Pols H, Felsenberg D, Hanley D, Stepan J, Munoz-Torres M, Wilkin T . Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999; 9(5):461-8. DOI: 10.1007/pl00004171. View

Wilkinson J, Stockley I, Peel N, Hamer A, Elson R, Barrington N . Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res. 2001; 16(3):556-64. DOI: 10.1359/jbmr.2001.16.3.556. View

Wilkinson J, Peel N, Elson R, Stockley I, Eastell R . Measuring bone mineral density of the pelvis and proximal femur after total hip arthroplasty. J Bone Joint Surg Br. 2001; 83(2):283-8. DOI: 10.1302/0301-620x.83b2.10562. View

Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi J . A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2001; 12(2):140-51. DOI: 10.1007/s001980170147. View

Venesmaa P, Kroger H, Miettinen H, Jurvelin J, Suomalainen O, Alhava E . Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry--a 3-year follow-up study. J Bone Miner Res. 2001; 16(6):1056-61. DOI: 10.1359/jbmr.2001.16.6.1056. View

10.

Venesmaa P, Kroger H, Miettinen H, Jurvelin J, Suomalainen O, Alhav E . Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001; 16(11):2126-31. DOI: 10.1359/jbmr.2001.16.11.2126. View

11.

Venesmaa P, Kroger H, Jurvelin J, Miettinen H, Suomalainen O, Alhava E . Periprosthetic bone loss after cemented total hip arthroplasty: a prospective 5-year dual energy radiographic absorptiometry study of 15 patients. Acta Orthop Scand. 2003; 74(1):31-6. DOI: 10.1080/00016470310013617 . View

12.

Yamaguchi K, Masuhara K, Yamasaki S, Nakai T, Fuji T . Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone. 2003; 33(1):144-9. DOI: 10.1016/s8756-3282(03)00085-1. View

13.

Nehme A, Maalouf G, Tricoire J, Giordano G, Chiron P, Puget J . [Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study]. Rev Chir Orthop Reparatrice Appar Mot. 2003; 89(7):593-8. View

14.

Oh I, Harris W . Proximal strain distribution in the loaded femur. An in vitro comparison of the distributions in the intact femur and after insertion of different hip-replacement femoral components. J Bone Joint Surg Am. 1978; 60(1):75-85. View

15.

Gruen T, McNeice G, Amstutz H . "Modes of failure" of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979; (141):17-27. View

16.

Storm T, Thamsborg G, Steiniche T, Genant H, Sorensen O . Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990; 322(18):1265-71. DOI: 10.1056/NEJM199005033221803. View

17.

Watts N, Harris S, Genant H, Wasnich R, Miller P, Jackson R . Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323(2):73-9. DOI: 10.1056/NEJM199007123230201. View

18.

Harris S, Watts N, Jackson R, Genant H, Wasnich R, Ross P . Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993; 95(6):557-67. DOI: 10.1016/0002-9343(93)90350-x. View

19.

Dunn C, Fitton A, Sorkin E . Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994; 5(6):446-74. DOI: 10.2165/00002512-199405060-00006. View

20.

Cohen B, Rushton N . Accuracy of DEXA measurement of bone mineral density after total hip arthroplasty. J Bone Joint Surg Br. 1995; 77(3):479-83. View